BILLERICA, Mass. & MADISON, Wis., July 3 -- Bruker Daltonics Inc. and Bruker AXS Inc. announced this week that they have completed the merger of the two companies, which was approved by approximately 94 percent of the Bruker Daltonics stockholders and 94 percent of the Bruker AXS stockholders at stockholder meetings on June 27. Bruker Daltonics develops life science tools based on mass spectrometry; Bruker AXS provides life science and advanced materials research tools based on x-ray technology. The combined company is named Bruker BioSciences Corp., and has begun trading on NASDAQ under the symbol BRKR. In connection with the merger, Bruker BioSciences has formed two operating subsidiaries, Bruker AXS Inc. and Bruker Daltonics Inc., into which it has transferred substantially all of the assets and liabilities, except cash, that formerly belonged to Bruker AXS and Bruker Daltonics.
As a result of the merger, Bruker BioSciences said it will offer a broader technology base and product portfolio, and will increase its global distribution, sales and service infrastructure. Bruker BioSciences said it will have a more diversified customer base, including pharmaceutical, diagnostics, biotech, academia and government.
Martin Haase, vice chairman and senior vice president of Bruker BioSciences, said: "The combination of Bruker AXS and Bruker Daltonics will bring together the technologies of mass spectrometry and x-ray analysis, allowing us to provide our life science and materials research customers with an even broader range of products."
The combined company will host an investor and analyst open house at its headquarters in Billerica, Mass., on July 11.
For more information, visit: www.bdal.com